JP3844504B2 - アシル化タンパク質粉末の製造 - Google Patents

アシル化タンパク質粉末の製造 Download PDF

Info

Publication number
JP3844504B2
JP3844504B2 JP50083297A JP50083297A JP3844504B2 JP 3844504 B2 JP3844504 B2 JP 3844504B2 JP 50083297 A JP50083297 A JP 50083297A JP 50083297 A JP50083297 A JP 50083297A JP 3844504 B2 JP3844504 B2 JP 3844504B2
Authority
JP
Japan
Prior art keywords
acylated
protein
insulin
fatty acid
fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50083297A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11506738A5 (enExample
JPH11506738A (ja
Inventor
ベイカー，ジェフリー・クレイトン
モザー，ブライアン・エイ
シュレーダー，ウォーレン・イー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JPH11506738A publication Critical patent/JPH11506738A/ja
Publication of JPH11506738A5 publication Critical patent/JPH11506738A5/ja
Application granted granted Critical
Publication of JP3844504B2 publication Critical patent/JP3844504B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP50083297A 1995-06-07 1996-06-04 アシル化タンパク質粉末の製造 Expired - Fee Related JP3844504B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/484,220 US5700904A (en) 1995-06-07 1995-06-07 Preparation of an acylated protein powder
US08/484,220 1995-06-07
PCT/US1996/007963 WO1996040730A1 (en) 1995-06-07 1996-06-04 Preparation of an acylated protein powder

Publications (3)

Publication Number Publication Date
JPH11506738A JPH11506738A (ja) 1999-06-15
JPH11506738A5 JPH11506738A5 (enExample) 2004-07-22
JP3844504B2 true JP3844504B2 (ja) 2006-11-15

Family

ID=23923252

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50083297A Expired - Fee Related JP3844504B2 (ja) 1995-06-07 1996-06-04 アシル化タンパク質粉末の製造

Country Status (21)

Country Link
US (1) US5700904A (enExample)
EP (1) EP0747391B1 (enExample)
JP (1) JP3844504B2 (enExample)
KR (1) KR19990022590A (enExample)
CN (1) CN1192218A (enExample)
AT (1) ATE263185T1 (enExample)
AU (1) AU703032B2 (enExample)
BR (1) BR9608729A (enExample)
CA (1) CA2223389A1 (enExample)
CZ (1) CZ388197A3 (enExample)
DE (1) DE69631996T2 (enExample)
DK (1) DK0747391T3 (enExample)
EA (1) EA199800042A1 (enExample)
ES (1) ES2216039T3 (enExample)
HU (1) HUP9900877A3 (enExample)
IL (1) IL122460A0 (enExample)
NO (1) NO975583D0 (enExample)
NZ (1) NZ309371A (enExample)
PL (1) PL323994A1 (enExample)
TR (1) TR199701528T1 (enExample)
WO (1) WO1996040730A1 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US5986050A (en) * 1996-12-26 1999-11-16 Poly-Med, Inc. Peracylated proteins and synthetic polypeptides and process for making the same
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
AU5749198A (en) * 1997-02-07 1998-08-26 Novo Nordisk A/S Crystallisation of proteins
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
RU2198181C2 (ru) * 1997-03-20 2003-02-10 Ново Нордиск А/С Не содержащие цинк кристаллы инсулина для применения в легочных композициях
TR200001050T2 (tr) * 1997-10-24 2000-08-21 Eli Lilly And Company Çözünmez insülin bileşimleri
ZA989644B (en) * 1997-10-24 2000-04-25 Lilly Co Eli Insoluble insulen compositions.
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
EP1396272A1 (en) * 1997-12-23 2004-03-10 Eli Lilly & Company Insoluble Insulin Compositions for Controlling Blood Glucose
US6526675B1 (en) * 1999-06-07 2003-03-04 Roe-Hoan Yoon Methods of using natural products as dewatering aids for fine particles
US6855260B1 (en) * 1999-06-07 2005-02-15 Roe-Hoan Yoon Methods of enhancing fine particle dewatering
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6799682B1 (en) 2000-05-16 2004-10-05 Roe-Hoan Yoon Method of increasing flotation rate
US6663602B2 (en) 2000-06-16 2003-12-16 Novo Nordisk A/S Injection device
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2003088961A1 (en) * 2002-04-19 2003-10-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20060247216A1 (en) * 2002-10-25 2006-11-02 Haj-Yehia Abdullah I Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
CA2820537C (en) 2003-04-23 2015-10-20 Valeritas, Inc. Hydraulically actuated pump for fluid administration
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
WO2006014673A2 (en) 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
PL1804865T3 (pl) 2004-10-21 2010-03-31 Novo Nordisk As Mechanizm wkręcania dla nawijanych penów
JP4022595B2 (ja) * 2004-10-26 2007-12-19 コニカミノルタオプト株式会社 撮影装置
CA2597176C (en) 2005-02-04 2013-10-22 Mineral And Coal Technologies, Inc. Improving the separation of diamond from gangue minerals
US20090043264A1 (en) 2005-04-24 2009-02-12 Novo Nordisk A/S Injection Device
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
RU2485106C2 (ru) * 2005-06-08 2013-06-20 Райджел Фамэсьютикэлз, Инк. Соединения, проявляющие активность в отношении jak-киназы (варианты), способ лечения заболеваний, опосредованных jak-киназой, способ ингибирования активности jak-киназы (варианты), фармацевтическая композиция на основе указанных соединений
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8962643B2 (en) * 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8361036B2 (en) 2006-03-10 2013-01-29 Novo Nordisk A/S Injection device having a gearing arrangement
JP5062768B2 (ja) 2006-03-10 2012-10-31 ノボ・ノルデイスク・エー／エス 注射装置および該装置のカートリッジを交換する方法
EP2004671B1 (en) 2006-03-30 2015-12-09 Novo Nordisk A/S Two-phase precipitation of proteins
ES2656675T3 (es) 2006-03-30 2018-02-28 Valeritas, Inc. Dispositivo de suministro de fluidos de múltiples cartuchos
US7714025B2 (en) * 2006-05-10 2010-05-11 Arizona Biomedical Research Commission Modified chalcone compounds as antimitotic agents
US8226618B2 (en) 2006-05-16 2012-07-24 Novo Nordisk A/S Gearing mechanism for an injection device
AU2007253481B2 (en) 2006-05-18 2013-01-17 Novo Nordisk A/S An injection device with mode locking means
CA2681023C (en) 2007-03-23 2015-11-03 Novo Nordisk A/S An injection device comprising a locking nut
KR101234540B1 (ko) 2007-10-16 2013-02-19 바이오콘 리미티드 경구 투여가능한 고형 약제학적 조성물 및 그 제조방법
HRP20151325T1 (hr) 2009-01-23 2016-01-01 Rigel Pharmaceuticals, Inc. Pripravci i postupci za inhibiciju jak puta
CN102770152B (zh) 2009-11-25 2016-07-06 阿瑞斯根股份有限公司 肽类的粘膜递送
WO2012015972A1 (en) 2010-07-28 2012-02-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2797650A2 (en) 2011-12-29 2014-11-05 Novo Nordisk A/S Torsion-spring based wind-up autoinjector pen with dial-up/dial-down dosing mechanism
WO2013142038A2 (en) 2012-03-23 2013-09-26 Oxigene, Inc. Compositions and methods for inhibition of cathepsins
US11206846B2 (en) * 2017-05-02 2021-12-28 Leprino Foods Company High purity alpha lactalbumin and methods of making
WO2019064125A1 (en) 2017-09-26 2019-04-04 Biocon Limited INTEGRATED AUTOMATED FILTRATION FOR THE SEPARATION, WASHING AND DRYING OF PEPTIDE CRYSTALS
US20220000880A1 (en) 2018-11-01 2022-01-06 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
US20200377518A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
CA3147443A1 (en) 2019-08-08 2021-02-11 Rigel Pharmaceuticals, Inc. Compounds and method for treating cytokine release syndrome
ES2970382T3 (es) 2019-08-14 2024-05-28 Rigel Pharmaceuticals Inc Método para bloquear o mejorar el síndrome de liberación de citocinas
JP2025513716A (ja) 2022-03-23 2025-04-30 ライジェル・ファーマシューティカルズ・インコーポレイテッド Ｉｒａｋ阻害剤としてのピリミド－２－イル－ピラゾール化合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1468831A (fr) * 1965-10-05 1967-02-10 Roussel Uclaf Procédé de préparation de nouveaux composés polypeptidiques et produits en résultant
DE1902865A1 (de) * 1968-02-01 1969-09-11 American Home Prod Substituierte Insulin-Derivate,Verfahren zu ihrer Herstellung und ihre Verwendung in pharmazeutischen Zubereitungen
US3591574A (en) * 1968-05-29 1971-07-06 American Home Prod Tri-n-phenylglycyl derivatives of insulin
US3528960A (en) * 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3823125A (en) * 1969-10-14 1974-07-09 American Home Prod N-aminoacyl-substituted insulins
US3752798A (en) * 1969-12-02 1973-08-14 G Amird Tris-na1,nb1,nepsilonb29 - (3-x-3-oxo - 1-y-prop-1-en-1-yl)(ndelta-(4-z-6-r-pyrimidin - 2 - yl) ornithine b22)-insulins and their preparation
US3869437A (en) * 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3864325A (en) * 1971-11-18 1975-02-04 Nat Res Dev (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives
BE791949A (fr) * 1971-11-27 1973-05-28 Schering Ag Derives d'insuline, leur preparation et leur utilisation
US3843815A (en) * 1972-02-10 1974-10-22 Gen Foods Corp Inhibiting gel formation in meat-in-gravy products
US3755569A (en) * 1972-07-25 1973-08-28 American Home Prod Acyl substituted insulins
DE2252157C3 (de) * 1972-10-25 1976-03-18 Hoechst Ag Zwischenprodukte zur herstellung von insulin, insulin-analogen und -derivaten und verfahren zur herstellung von insulin, insulin analogen und derivaten
NL7314766A (enExample) * 1972-10-31 1974-05-02
DE2253327A1 (de) * 1972-10-31 1974-05-09 Hoechst Ag Verfahren zur herstellung von insulin, insulin-analogen und -derivaten
DE2428412A1 (de) * 1974-06-12 1976-01-15 Hoechst Ag Verfahren zur herstellung von insulin, insulin-analogen und -derivaten
DE2439296A1 (de) * 1974-08-16 1976-02-26 Hoechst Ag Verfahren zur herstellung von insulin, insulin-analogen und -derivaten
GB1492997A (en) * 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
EP0014815A3 (de) * 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4486458A (en) * 1982-09-07 1984-12-04 A. E. Staley Manufacturing Company Non-gelling corn steep liquor
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
JPS6255096A (ja) * 1986-06-12 1987-03-10 Nippon Shinyaku Co Ltd 新規な脂肪酸アシル化合物
JPH01254699A (ja) * 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
PT93057B (pt) * 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
WO1992001476A1 (en) * 1990-07-26 1992-02-06 University Of Iowa Research Foundation Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
US5304473A (en) * 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
AU5574094A (en) * 1992-11-30 1994-06-22 Biosignal Kutato-Fejleszto Kft. Polyunsaturated fatty acyl-peptide composition

Also Published As

Publication number Publication date
IL122460A0 (en) 1998-06-15
EA199800042A1 (ru) 1998-08-27
DE69631996D1 (de) 2004-05-06
CA2223389A1 (en) 1996-12-19
KR19990022590A (ko) 1999-03-25
ATE263185T1 (de) 2004-04-15
HUP9900877A3 (en) 1999-11-29
DE69631996T2 (de) 2005-01-27
HUP9900877A2 (hu) 1999-07-28
WO1996040730A1 (en) 1996-12-19
US5700904A (en) 1997-12-23
AU5951396A (en) 1996-12-30
ES2216039T3 (es) 2004-10-16
AU703032B2 (en) 1999-03-11
TR199701528T1 (xx) 1998-03-21
NO975583L (no) 1997-12-03
EP0747391B1 (en) 2004-03-31
EP0747391A2 (en) 1996-12-11
MX9709657A (es) 1998-07-31
PL323994A1 (en) 1998-04-27
DK0747391T3 (da) 2004-07-19
JPH11506738A (ja) 1999-06-15
NO975583D0 (no) 1997-12-03
BR9608729A (pt) 1999-06-29
NZ309371A (en) 1999-09-29
CZ388197A3 (cs) 1998-05-13
CN1192218A (zh) 1998-09-02
EP0747391A3 (en) 1997-05-21

Similar Documents

Publication Publication Date Title
JP3844504B2 (ja) アシル化タンパク質粉末の製造
JP3962430B2 (ja) 脂肪酸アシル化蛋白質のゲル化削減法
EP0254516B1 (en) Novel Peptides
EP0194864B1 (en) Novel peptides
US5898067A (en) Crystallization of proteins
CA1246549A (en) Crystal suspensions of insulin derivatives, processes for their preparation and their use
AU1397688A (en) Novel insulin derivatives
IE57690B1 (en) Pharmaceutical agent for the treatment of diabetes mellitus
EP0536245A1 (en) Novel, protracted insulin analogues
CN1171742A (zh) ε－氨基的选择性酰化
US20040242460A1 (en) Stabilized acylated insulin formulations
US20230220000A1 (en) Process for preparing a glp-1/glucagon dual agonist
EP0966482B1 (en) Crystallisation of proteins
US5466666A (en) Amorphous monospheric forms of insulin derivatives
MXPA97009657A (en) Preparation of an acil protein dust
EP0277043A2 (en) Method for recovering somatotropins from dilute aqueous solution
JPH01500829A (ja) 医薬組成物のためのスクシニル化されたインターロイキン―２
HK1014010A (en) Reducing gelation of a fatty acid acylated protein using a citrate buffer

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20051213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060303

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060816

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110220

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120220

Year of fee payment: 14

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120220

Year of fee payment: 14

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130220

Year of fee payment: 15